SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08. Februar 2024 08:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics Announces Executive Leadership Change
02. Februar 2024 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
23. Januar 2024 17:58 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
02. Januar 2024 16:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human...
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
29. November 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) SAB-142 directly and specifically targets multiple...
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
20. November 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a...
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
14. November 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditionsParticipating investors include Sessa Capital, BVF Partners, RTW...
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
14. November 2023 07:15 ET
|
SAB Biotherapeutics, Inc.
Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human Research Ethics Committee (HREC) to commence a...
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
09. November 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
24. Oktober 2023 07:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a...